- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months
This study is looking at how safe new vaccines are for babies aged 5 to 23 months. It's testing two different vaccines (mRNA-1345 and mRNA-1365) to see if they help protect against chest infections, like those caused by RSV. Scientists are checking for any side effects and how well the vaccines boost the babies' immune systems.
For: Acute lower respiratory infectionSpain · Latvia · Poland - Active not recruitingPHASE1
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
This study is testing new mRNA vaccines against common winter viruses, RSV and hMPV, in babies and toddlers aged 5 to 24 months. Researchers want to see if the vaccines are safe and good at triggering the body's immune response.
For: Respiratory Syncytial Virus · Human MetapneumovirusUnited States · Australia · Canada